Thus, in future, it will be critical to test the therapeutic value of specific inhibitors of P‐cadherin in GBM, some of which have been already developed [75, 76, 77, 78, 79] and completed phase 1 clinical trials [e.g., an immunoconjugate PCA062 (NCT02375958) and an anti‐P‐cadherin/anti‐CD3‐bispecific molecule PF‐06671008 (NCT02659631)] in solid tumors, including triple‐negative breast cancer, head and neck cancer, and esophageal cancer. The gene discussed is CDH3; the disease is head and neck cancer.